IL315473A - A new treatment for FACIOSCAPULOHUMERAL MUSCLE DYSFUNCTION (FSHD) - Google Patents

A new treatment for FACIOSCAPULOHUMERAL MUSCLE DYSFUNCTION (FSHD)

Info

Publication number
IL315473A
IL315473A IL315473A IL31547324A IL315473A IL 315473 A IL315473 A IL 315473A IL 315473 A IL315473 A IL 315473A IL 31547324 A IL31547324 A IL 31547324A IL 315473 A IL315473 A IL 315473A
Authority
IL
Israel
Prior art keywords
fshd
muscular dystrophy
new treatment
facioscapulohumeral muscular
facioscapulohumeral
Prior art date
Application number
IL315473A
Other languages
English (en)
Hebrew (he)
Inventor
Eleni Gaki
Tammy Mciver
Scalco Renata Siciliani
Kathryn Rae Wagner
Wai Yin Yeung
Original Assignee
Hoffmann La Roche
Eleni Gaki
Tammy Mciver
Scalco Renata Siciliani
Kathryn Rae Wagner
Wai Yin Yeung
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche, Eleni Gaki, Tammy Mciver, Scalco Renata Siciliani, Kathryn Rae Wagner, Wai Yin Yeung filed Critical Hoffmann La Roche
Publication of IL315473A publication Critical patent/IL315473A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IL315473A 2022-04-01 2023-03-30 A new treatment for FACIOSCAPULOHUMERAL MUSCLE DYSFUNCTION (FSHD) IL315473A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP22166261 2022-04-01
PCT/EP2023/058218 WO2023187022A1 (en) 2022-04-01 2023-03-30 New treatment for facioscapulohumeral muscular dystrophy (fshd)

Publications (1)

Publication Number Publication Date
IL315473A true IL315473A (en) 2024-11-01

Family

ID=81328333

Family Applications (1)

Application Number Title Priority Date Filing Date
IL315473A IL315473A (en) 2022-04-01 2023-03-30 A new treatment for FACIOSCAPULOHUMERAL MUSCLE DYSFUNCTION (FSHD)

Country Status (11)

Country Link
US (1) US20250171526A1 (https=)
EP (1) EP4504779A1 (https=)
JP (1) JP2025511167A (https=)
KR (1) KR20240165959A (https=)
CN (1) CN119053619A (https=)
AU (1) AU2023246859A1 (https=)
CA (1) CA3255735A1 (https=)
IL (1) IL315473A (https=)
MX (1) MX2024011922A (https=)
TW (1) TW202346345A (https=)
WO (1) WO2023187022A1 (https=)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
KR101860280B1 (ko) 2014-12-19 2018-05-21 추가이 세이야쿠 가부시키가이샤 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법
AR107078A1 (es) 2015-12-18 2018-03-21 Chugai Pharmaceutical Co Ltd Anticuerpo antimiostatina, polipéptidos que contienen regiones fc variantes así como métodos de uso

Also Published As

Publication number Publication date
AU2023246859A1 (en) 2024-09-05
TW202346345A (zh) 2023-12-01
AU2023246859A9 (en) 2024-09-12
EP4504779A1 (en) 2025-02-12
KR20240165959A (ko) 2024-11-25
JP2025511167A (ja) 2025-04-15
MX2024011922A (es) 2024-11-08
WO2023187022A1 (en) 2023-10-05
CN119053619A (zh) 2024-11-29
CA3255735A1 (en) 2023-10-05
US20250171526A1 (en) 2025-05-29

Similar Documents

Publication Publication Date Title
IL307937A (en) Treatment methods for muscular dystrophy
EP4291902A4 (en) BIOMARKERS FOR CANCER TREATMENT
EP4101018A4 (en) Chemical treatment for the production of metal electrodes
IL315473A (en) A new treatment for FACIOSCAPULOHUMERAL MUSCLE DYSFUNCTION (FSHD)
EP3965778A4 (en) METHOD OF TREATMENT OF MUSCULAR DYSTROPHY USING INHIBITORY OLIGONUCLEOTIDES AGAINST CD49D
SG11202108469XA (en) Compositions and methods for treating oculopharyngeal muscular dystrophy (opmd)
IL304550A (en) Biomarkers for fimpinostat therapy
GB2611611B (en) Multiple inlet apparatus for isotope ratio spectrometry
HK40103282A (en) Compositions and methods for treating facioscapulohumeral muscular dystrophy (fshd)
EP3866859A4 (en) METHODS OF TREATMENT FOR OCULOPHARYNGEAL MUSCULAR DYSTROPHY (OPMD)
HK40088953A (en) Crispr-inhibition for facioscapulohumeral muscular dystrophy
IL296783B2 (en) Wastewater gas treatment device
HK40104293A (en) Treatment methods for muscular dystrophy
GB2631471B (en) Apparatus for inductively coupled plasma mass spectrometry
KR102963392B1 (ko) 차량용 슬림형 램프 장치
GB202408028D0 (en) inhaler apparatus
EM151397530004S (bg) уреди за гимнастика (Част от -)
EM151397530003S (bg) уреди за гимнастика (Част от -)
EM151397530006S (mt) Apparat tal-ġinnastika
EM151397530001S (bg) уреди за гимнастика
EM151397530005S (bg) уреди за гимнастика
EM151397530002S (mt) Apparat tal-ġinnastika
EM151389540001S (bg) уреди за гимнастика
EM151383030003S (mt) Apparat tal-ġinnastika
EM151383030001S (nl) Gymnastiek- en turntoestellen